CAL
VIR icon

Capital Analysts LLC’s Vir Biotechnology VIR Stock Holding History

Capital Analysts LLC’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-320
Closed -$3K – 1367
2024
Q2 		$3K Hold
320
– – ﹤0.01% 1093
2024
Q1 		$3K Hold
320
– – ﹤0.01% 1039
2023
Q4 		$3K Hold
320
– – ﹤0.01% 1006
2023
Q3 		$3K Sell
320
-15
-4% -$214 ﹤0.01% 1037
2023
Q2 		$8K Hold
335
– – ﹤0.01% 846
2023
Q1 		$8K Buy
335
+90
+37% +$2.3K ﹤0.01% 827
2022
Q4 		$6K Hold
245
– – ﹤0.01% 903
2022
Q3 		$5K Buy
245
+50
+26% +$1.27K ﹤0.01% 896
2022
Q2 		$5K Buy
+195
New +$4.55K ﹤0.01% 871

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Analysts LLC's VIR Position: Q3 2024 in Review

Capital Analysts LLC sold out of Vir Biotechnology (VIR) in Q3 2024, closing a stake of 320 shares — an estimated $3K sold.

Capital Analysts LLC first reported a position in VIR in Q2 2022 and held it in 9 quarters. The position peaked at $8K in Q2 2023. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

  • Capital Analysts LLC reported no remaining Vir Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Capital Analysts LLC sold 320 Vir Biotechnology shares in Q3 2024, an estimated $3K.
  • Capital Analysts LLC first reported a position in Vir Biotechnology in Q2 2022 and held it in 9 quarters.
  • Capital Analysts LLC's Vir Biotechnology position peaked at $8K in Q2 2023.
  • 197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Capital Analysts LLC's 13F filing for Q3 2024, filed 13 Nov 2024.